| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144609 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months from now) | |
| US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months from now) | |
| US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months from now) | |
| US9561277 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months from now) | |
| US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months from now) | |
| US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months from now) | |
| US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(9 years from now) | |
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(10 years from now) | |
Prolensa is owned by Bausch And Lomb.
Prolensa contains Bromfenac Sodium.
Prolensa has a total of 9 drug patents out of which 0 drug patents have expired.
Prolensa was authorised for market use on 05 April, 2013.
Prolensa is available in solution/drops;ophthalmic dosage forms.
Prolensa can be used as method of treating ocular inflammation; method of treatment to alleviate inflammation of the eye; method of treating ocular inflammation, treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
The generics of Prolensa are possible to be released after 11 November, 2033.
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Method of treating ocular inflammation; Method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone ca...
Dosage: SOLUTION/DROPS;OPHTHALMIC
PROLENSA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic